Around one million people are currently living with dementia in the UK, including 29,000 across Kent and over 1,200 in my own ...

[1,2] The treatment was tested in a large 18-month clinical study in patients with mild cognitive impairment (MCI) and mild dementia due to early AD ... provider about the best way to feed ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

Approval for donanemab, another antibody treatment ... really effective at the really early stages of Alzheimer’s disease (and don’t work for vascular dementia, a type of dementia caused ...

For the first time, we are transitioning from an observational to an interventional clinical regime in how we approach dementia. These new therapies are disease- modifying treatments (DMTs). They need ...

for adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed ...

When people think about dementia ... treatments. The next steps for the research team will involve larger studies to confirm their findings and explore how brain stimulation might help people with ...

dementia and Parkinson’s disease. The new study by scientists at Nottingham Trent University will look at whether treatment can be delivered to the brain via specialised microbubbles.

Our study yielded three main findings: first, respondents were much less likely to recommend life-sustaining treatments for patients with dementia, especially after personal exposure. Second, ...

In Japan, by 2030, the number of patients with dementia is estimated to be more ... In the overall population, the response to treatment was also statistically significant using the iADRS at ...